Antiretroviral therapy during infancy: Essential intervention for resource-limited settings

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 5, 2008, Pages 585-589

  Eley, Brian S ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Highly active antiretroviral therapy; Infancy; Resource limited setting

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHILD CARE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERNATIONAL COOPERATION; LOWEST INCOME GROUP; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PERINATAL INFECTION; PRACTICE GUIDELINE; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

EID: 55249116805     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.5.585     Document Type: Article

References (18)

1. Prendergast A, Mphatswe W, Tudor-Williams G et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 22, 1333-1343 (2008).
2. HIV Paediatric Prognostic Markets Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362, 1605-1611 (2003).
3. Janssens B, Raleigh B, Soeung S et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 120, E1134-E1140 (2007).
4. George E, Noël F, Bois G et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J. Infect. Dis. 195, 1411-1418 (2007).
5. Wamalwa, DC, Farquhar C, Obimbo EM et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J. Acquir. Immune Defic. Syndr. 45, 311-317 (2007).
6. Reddi A, Leeper SC, Grobler AC et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from Kwazulu-Natal, South Africa. BMC Pediatr. 7, 13 (2007).
7. Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 46, 187-193 (2007).
8. Eley B, Davies M, Apolles P et al. Antiretroviral treatment for children. S. Afr. Med. J. 96, 988-993 (2006).
9. Rouet, F, Fassinou P, Inwoley A et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20, 2315-2319 (2006).
10. Puthanakit T, Oberdorfer A, Akarathum N et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin. Infect. Dis. 41, 100-107 (2005).
11. Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; for the Ghent International AIDS Society (AIS) working group on HIV infection in women and children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364, 1236-1243 (2007).
12. Mills EJ, Nachega JB, Buchan I et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. J. Am. Med. Assoc. 296, 679-690 (2006).
13. Faye A, Le Chenadec J, Dollfus C et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin. Infect. Dis. 39, 1692-1698 (2004).
14. Violari A, Cotton M, Gibb D et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Presented at: 4th IAS Conference Sydney, Australia, 22-25 July 2007.
15. Luzuriaga K, McManus M, Mofenson L et al. A trial of three antiretroviral regimens in HIV-1 infected children. N. Engl. J. Med. 350, 2471-2480 (2004).
16. Cherutich P, Inwani I, Nduati R, Mbori-Ngacha D. Optimizing paediatric HIV care in Kenya: challenges in early infant diagnosis. Bull. World Health Organ. 86, 155-160 (2008).
17. INITIO Trial International Co-ordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomized trial. Lancet 368, 287-298 (2006).
18. Gulick RM, Ribaudo HJ, Shikuma CM et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. J. Am. Med. Assoc. 296, 769-781 (2006).